EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Consolidation With Hyper-CVAD or VP Plus Dasatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Controlled Trial

Xiaoyan Zheng, Ruimin Liu, Juan Ren, Huachao Zhu, Pengcheng He, Xiaoning Wang

Clinical Lymphoma Myeloma and Leukemia · 2026-10

DOI: 10.1016/j.clml.2026.10.014 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Xiaoyan Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, PR China. Die Arbeit nennt 19 Literaturangaben. Gefördert von: National Natural Science Foundation of China National Outstanding Youth Science Fund Project, Key Science and Technology Program of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: For Ph+ acute lymphoblastic leukemia (ALL) patients achieving complete molecular response (CMR) pre-transplantation is critical, particularly for those ineligible for bispecific antibodies or CAR-T therapy. OBJECTIVE: To compare the efficacy of 2-4 cycles of VP versus Hyper-CVAD with dasatinib as consolidation therapy in Ph+ ALL. METHODS: This single-center, randomized controlled trial (NCT05026229) enrolled patients aged ≥ 18 years with de novo Ph+ ALL. After 1 cycle of VP (vincristine plus prednisone) plus dasatinib induction, patients were randomized to VP (Arm A) or Hyper-CVAD Part B (high-dose methotrexate and high-dose cytarabine, Arm B) consolidation. Primary endpoint was CMR after cycle 4. Secondary endpoints included CMR rate after cycle 2, CIR, PFS, OS and safety. RESULTS: 31 patients were enrolled before early termination due to excess relapse in the Arm A. For Arm A and Arm B, after cycle 2, CMR rates were 5.6% and 53.8%, and after cycle 4, CMR rates were 5.6% and 69.2%, respectively. With a median follow-up of 40 months, 3-year OS and PFS of Arm A and Arm B were 68.2% versus 57.1% (P = .16), and 31.8% versus 54.8%, respectively (P = .022). CONCLUSION: In Ph+ ALL patients ineligible for cellular immunotherapy, Hyper-CVAD demonstrated superior CMR rates, lower relapse risk, and significantly improved PFS compared with VP, despite no OS difference. The VP arm was terminated early due to high relapse rates, suggesting VP is not recommended as a preferred strategy in this population.

Schlagwörter

Stichwörter der Autor:innen

Allogeneic hematopoietic stem cell transplantationComplete molecular responsePhiladelphia-positive acute lymphoblastic leukemiaRelapse

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, PR China.
  • Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, PR China. Electronic address: wangxn99@163.com.

Förderung

  • National Natural Science Foundation of China National Outstanding Youth Science Fund Project
  • Key Science and Technology Program of Shaanxi Province

Zitieren

APA

Zheng, X., Liu, R., Ren, J., Zhu, H., He, P., & Wang, X. (2026). Consolidation With Hyper-CVAD or VP Plus Dasatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Controlled Trial. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.014

Vancouver

Zheng X, Liu R, Ren J, Zhu H, He P, Wang X. Consolidation With Hyper-CVAD or VP Plus Dasatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Controlled Trial. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.014

BibTeX
@article{Zheng2026,
  author = {Zheng, Xiaoyan and Liu, Ruimin and Ren, Juan and Zhu, Huachao and He, Pengcheng and Wang, Xiaoning},
  title = {Consolidation With Hyper-CVAD or VP Plus Dasatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Controlled Trial},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.10.014}
}
Kostenlos starten →